{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T04:40:15Z","timestamp":1766983215774,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"crossref","award":["H25-iryogijutsu-ippan-008"],"award-info":[{"award-number":["H25-iryogijutsu-ippan-008"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["151k0201021h0003","18lk0201082h0001"],"award-info":[{"award-number":["151k0201021h0003","18lk0201082h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1099-7","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T02:31:25Z","timestamp":1541039485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07)"],"prefix":"10.1186","volume":"19","author":[{"given":"Tomoko","family":"Horinouchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Sako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari Saito","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-8174","authenticated-orcid":false,"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"issue":"9384","key":"1099_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629\u201339.","journal-title":"Lancet"},{"issue":"4","key":"1099_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10157-016-1319-z","volume":"21","author":"K Kikunaga","year":"2017","unstructured":"Kikunaga K, Ishikura K, Terano C, Sato M, Komaki F, Hamasaki Y, Sasaki S, Iijima K, Yoshikawa N, Nakanishi K, et al. High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study). Clin Exp Nephrol. 2017;21(4):651\u20137.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"1099_CR3","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/S0022-3476(88)80570-5","volume":"113","author":"SL Schulman","year":"1988","unstructured":"Schulman SL, Kaiser BA, Polinsky MS, Srinivasan R, Baluarte HJ. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr. 1988;113(6):996\u20131001.","journal-title":"J Pediatr"},{"issue":"7","key":"1099_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/adc.57.7.544","volume":"57","author":"O Koskimies","year":"1982","unstructured":"Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Arch Dis Child. 1982;57(7):544\u20138.","journal-title":"Arch Dis Child"},{"issue":"5","key":"1099_CR5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","volume":"8","author":"P Tarshish","year":"1997","unstructured":"Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the international study of kidney disease in children. J Am Soc Nephrol. 1997;8(5):769\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1099_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10157-014-1030-x","volume":"19","author":"K Ishikura","year":"2015","unstructured":"Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, et al. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol. 2015;19(1):6\u201333.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"1099_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/kisup.2012.16","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. Chapter 3: steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl. 2012;2(2):163\u201371.","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"1099_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00467-012-2393-4","volume":"28","author":"Y Hamasaki","year":"2013","unstructured":"Hamasaki Y, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Ito S, Kaneko T, et al. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol (Berlin, Germany). 2013;28(5):765\u201371.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"1","key":"1099_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s004670050558","volume":"13","author":"Y Inoue","year":"1999","unstructured":"Inoue Y, Iijima K, Nakamura H, Yoshikawa N. Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 1999;13(1):33\u20138.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"5","key":"1099_CR10","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1046\/j.1523-1755.2002.00303.x","volume":"61","author":"K Iijima","year":"2002","unstructured":"Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002;61(5):1801\u20135.","journal-title":"Kidney Int"},{"issue":"9950","key":"1099_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273\u201381.","journal-title":"Lancet"},{"issue":"7","key":"1099_CR12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol (Berlin, Germany). 2004;19(7):794\u20137.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"6","key":"1099_CR13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(6):1308\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1099_CR14","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol (Berlin, Germany). 2009;24(7):1321\u20138.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"3","key":"1099_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","volume":"25","author":"S Fujinaga","year":"2010","unstructured":"Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol (Berlin, Germany). 2010;25(3):539\u201344.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"8","key":"1099_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol (Berlin, Germany). 2008;23(8):1269\u201379.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"7","key":"1099_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","volume":"61","author":"The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group","year":"1996","unstructured":"The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61(7):1029\u201337.","journal-title":"Transplantation"},{"key":"1099_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000059931","volume":"124","author":"Y Vanrenterghem","year":"1998","unstructured":"Vanrenterghem Y. The use of mycophenolate mofetil (Cellcept) in renal transplantation. Contrib Nephrol. 1998;124:64\u20139 discussion 69-75.","journal-title":"Contrib Nephrol"},{"issue":"16","key":"1099_CR19","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou nephrology study group. N Engl J Med. 2000;343(16):1156\u201362.","journal-title":"N Engl J Med"},{"issue":"5","key":"1099_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00467-006-0060-3","volume":"21","author":"KK Lau","year":"2006","unstructured":"Lau KK, Jones DP, Hastings MC, Gaber LW, Ault BH. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr Nephrol (Berlin, Germany). 2006;21(5):655\u201362.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"12","key":"1099_CR21","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00467-007-0617-9","volume":"22","author":"K Afzal","year":"2007","unstructured":"Afzal K, Bagga A, Menon S, Hari P, Jordan SC. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2007;22(12):2059\u201365.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"6","key":"1099_CR22","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1053\/j.ajkd.2003.08.011","volume":"42","author":"A Bagga","year":"2003","unstructured":"Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis. 2003;42(6):1114\u201320.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1099_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00467-003-1175-4","volume":"18","author":"GM Barletta","year":"2003","unstructured":"Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2003;18(8):833\u20137.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"4","key":"1099_CR24","first-page":"268","volume":"72","author":"S Fujinaga","year":"2009","unstructured":"Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol. 2009;72(4):268\u201373.","journal-title":"Clin Nephrol"},{"issue":"1","key":"1099_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00467-006-0294-0","volume":"22","author":"S Fujinaga","year":"2007","unstructured":"Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2007;22(1):71\u20136.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"1","key":"1099_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00467-003-1300-4","volume":"19","author":"J Gellermann","year":"2004","unstructured":"Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol (Berlin, Germany). 2004;19(1):101\u20134.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"6","key":"1099_CR27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.00550206","volume":"1","author":"RJ Hogg","year":"2006","unstructured":"Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the southwest pediatric nephrology study group. Clin J Am Soc Nephrol. 2006;1(6):1173\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1099_CR28","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00467-005-1877-x","volume":"20","author":"S Mendizabal","year":"2005","unstructured":"Mendizabal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J. Mycophenolate mofetil in steroid\/cyclosporine-dependent\/resistant nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2005;20(7):914\u20139.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"6","key":"1099_CR29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1442-200X.2007.02487.x","volume":"49","author":"M Okada","year":"2007","unstructured":"Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int. 2007;49(6):933\u20137.","journal-title":"Pediatr Int"},{"issue":"4","key":"1099_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00467-004-1778-4","volume":"20","author":"T Ulinski","year":"2005","unstructured":"Ulinski T, Dubourg L, Said MH, Parchoux B, Ranchin B, Cochat P. Switch from cyclosporine a to mycophenolate mofetil in nephrotic children. Pediatr Nephrol (Berlin, Germany). 2005;20(4):482\u20135.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"10","key":"1099_CR31","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2011;26(10):1823\u20138.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"10","key":"1099_CR32","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00467-011-1894-x","volume":"26","author":"G Filler","year":"2011","unstructured":"Filler G, Huang SH, Sharma AP. Should we consider MMF therapy after rituximab for nephrotic syndrome? Pediatr Nephrol (Berlin, Germany). 2011;26(10):1759\u201362.","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"issue":"7654","key":"1099_CR33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0140-6736(70)91093-7","volume":"1","author":"M Abramowicz","year":"1970","unstructured":"Abramowicz M, Barnett HL, Edelmann CM Jr, Greifer I, Kobayashi O, Arneil GC, Barron BA, Gordillo PG, Hallman N, Tiddens HA. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children. Lancet. 1970;1(7654):959\u201361.","journal-title":"Lancet"},{"issue":"2","key":"1099_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","volume":"21","author":"K Iijima","year":"2017","unstructured":"Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21(2):193\u2013202.","journal-title":"Clin Exp Nephrol"},{"key":"1099_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-065X.1993.tb00652.x","volume":"136","author":"AC Allison","year":"1993","unstructured":"Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 1993;136:5\u201328.","journal-title":"Immunol Rev"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1099-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1099-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1099-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:39:18Z","timestamp":1662338358000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1099-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1099-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2018,11,1]]},"assertion":[{"value":"7 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is performed in accordance with the Declaration of Helsinki and is approved by the Institutional Review Board of Kobe University Graduate School of Medicine. Before enrollment, patients\u2019 guardians provided written informed consent, and informed assent was obtained from older children.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mayumi Sako has received a consulting fee from Zenyaku Kogyo Co. Ltd. Koichi Nakanishi has received lecture fees from Novartis Pharma K.K. Kenji Ishikura has received a grant from Chugai Pharmaceutical Co., Ltd. and Pfizer Japan Inc. and a lecture fee from Zenyaku Kogyo Co. Ltd. Kandai Nozu has received lecture fees from Chugai Pharmaceutical Co., Ltd. Kazumoto Iijima has received lecture fees and\/or consulting fees from Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co. Ltd., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Kyowa Hakko Kirin Co. Ltd.MMF is provided by Chugai Pharmaceutical Co., Ltd. The sponsor approved the study protocol, but had no role in data collection, data analysis and drafting or approving the present manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"302"}}